INDV Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -1.46%, SMA50 -2.74%, SMA200 33.96%). The stock’s 14-day RSI is 46.73 (neutral), while the ATR of 1.26 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -11.29% below its high and over 319.28% above its low. Average 10-day trading volume of 3.35 million shares is significantly above the 3-month average of 1.93 million, indicating heightened recent market interest.

Indivior Pharmaceuticals Inc generated EPS of $1.00 over the past year. Five-year average earnings growth is -56.08%. Wall Street analysts project EPS growth of 26.21% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $48.00 to $34.00. The high target offers 24.13% upside. The low target suggests -12.08% downside. The mean target is $41.17. This offers 6.46% upside. Indivior Pharmaceuticals Inc earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 03, 2026, missed forecasts by 29.36%. The prior quarter beat by 10.94%. Over the last six quarters, Apple has recorded several small beats. These include 86.36% in April 24, 2025.

Indivior Pharmaceuticals Inc has 118.20 million shares outstanding. The public float is 112.96 million shares, elevated short interest at 11.33% of float. This equals 11.28 million shares. The short ratio is 5.96 days. Institutional investors hold 112.0% of the float. Insiders own 1.97%. Preblick Ryan holds 284.75 thousand shares, Heidbreder Christian has 209.34 thousand shares and Anderson Woodrow D has 26.14 thousand shares. Over the past six months, insider transactions show net buying. They sold 73.17 thousand shares across 3 transactions.

Indivior Pharmaceuticals Inc last paid a dividend of 0.64 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.25. This means the shares are trading below this model’s fair value.

Indivior Pharmaceuticals Inc (NASDAQ:INDV) closed at $38.35 USD, losing -$0.32 (-0.84%) from the previous close of $38.67. The stock is currently mid-range between its 52-week high and low $21.83 and $42.81. With a market capitalization of about $4.78 billion, Indivior Pharmaceuticals Inc is classified as a mid-cap and shows market-like volatility (beta ~1.03). Key stats such as the average daily volume over the past year has been around 1.85 million shares, volume is running light vs its 52-week average. Headquartered in North Chesterfield, VA, Indivior Pharmaceuticals Inc operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Joseph J. Ciaffoni, the company employs approximately 833 people and listed since December 29, 2014. Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence.

Indivior Pharmaceuticals Inc trades at a P/E ratio of 13.75, slightly below the S&P 500 average, with a price-to-sales ratio of 3.66 and a price-to-book ratio of -23.54 indicating negative book value, which may reflect financial stress. The P/FCF stands at -43.91, also below market averages.

Indivior Pharmaceuticals Inc (NASDAQ:INDV) shares are flat -8.17% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Indivior Pharmaceuticals Inc trading at a premium to the broader market with a P/E of 13.75. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $28.60, suggesting -26.04% downside. Our AI forecast model points to short-term weakness (-13.29% over two weeks), a medium-term fall (-18.13% over three months), and a longer-term gain (21.21% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Indivior Pharmaceuticals Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -13.29%, with price expected at $33.53 by August 20, 2026, within a range of $32.22 to $34.71 3-Month Outlook: Projected fall of -18.13%, reaching $31.66 by November 04, 2026, with a range of $31.24 to $31.98. 1-Year Outlook: Projected gain of 21.21%, with price at $46.87 by August 06, 2027, within a range of $43.73 to $50.05.